Use of antibiotics by healthy elderly persons does not cause an increase in the risk of cognitive impairment or dementia, researchers reported on December 18, 2024 in Neurology…. read more.
Higher cardiorespiratory fitness in older age is linked to the preservation of several core aspects of cognitive ability that are vulnerable to age-related decline, finds research published online… read more.
Children of mothers who took certain antiseizure medications while pregnant do not have worse neurodevelopmental outcomes at age 6, according to a long-running study funded by the National… read more.
In cognitive science, there has recently been increasing attention to the relationship between sports expertise and working memory. However, to date, no meta-analysis has compared the working memory… read more.
A common yet underdiagnosed sleep disorder contributes to the development of dementia among adults — particularly women, a Michigan Medicine study suggests. Investigators uncovered this by examining survey… read more.
Eisai Co., Ltd and Biogen Inc. announced that the latest findings for lecanemab-irmb (U.S. brand name: Leqembi), an anti-amyloid beta (Aβ) protofibril antibody for the treatment of early… read more.
Polypharmacy, commonly defined as taking five or more medications daily, is a significant health care concern impacting over 30% of older adults. It is associated with poor health outcomes like… read more.
Lundbeck announced that Vyepti (eptinezumab) met the primary and all key secondary endpoints in SUNRISE, a phase III pivotal trial predominantly conducted in Asia evaluating the efficacy and… read more.
After only one to three days of a whiplash injury, scientists can predict which patients will develop chronic pain based on the extent of cross ‘talk’ between two… read more.
Eli Lilly and Company announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for donanemab, an injection for intravenous infusion every four weeks… read more.
Researchers report that patients treated with semaglutide have achieved a significantly lower risk of developing Alzheimer’s disease compared to those exposed to seven other anti-diabetic medications, including other… read more.
AbbVie announced that the FDA has approved Vyalev (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of motor fluctuations… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
